Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Bought by HBK Sorce Advisory LLC

HBK Sorce Advisory LLC raised its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) by 100.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 40,000 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. HBK Sorce Advisory LLC’s holdings in Ginkgo Bioworks were worth $46,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of DNA. Baillie Gifford & Co. boosted its stake in shares of Ginkgo Bioworks by 19.6% in the fourth quarter. Baillie Gifford & Co. now owns 244,176,643 shares of the company’s stock valued at $412,659,000 after buying an additional 40,099,800 shares in the last quarter. ARK Investment Management LLC boosted its position in shares of Ginkgo Bioworks by 13.9% in the fourth quarter. ARK Investment Management LLC now owns 144,384,067 shares of the company’s stock worth $244,009,000 after buying an additional 17,565,211 shares during the period. State Street Corp boosted its position in shares of Ginkgo Bioworks by 210.3% in the second quarter. State Street Corp now owns 12,411,855 shares of the company’s stock worth $29,540,000 after buying an additional 8,411,787 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Ginkgo Bioworks by 21.1% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 37,514,318 shares of the company’s stock valued at $63,399,000 after purchasing an additional 6,532,370 shares during the last quarter. Finally, Equitec Proprietary Markets LLC boosted its holdings in Ginkgo Bioworks by 78.5% in the fourth quarter. Equitec Proprietary Markets LLC now owns 4,081,452 shares of the company’s stock valued at $6,898,000 after purchasing an additional 1,795,187 shares during the last quarter. 61.83% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Ginkgo Bioworks news, major shareholder Barry Canton sold 75,300 shares of the firm’s stock in a transaction that occurred on Tuesday, March 14th. The shares were sold at an average price of $1.33, for a total transaction of $100,149.00. Following the completion of the sale, the insider now directly owns 13,918,194 shares in the company, valued at $18,511,198.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Ginkgo Bioworks news, insider Reshma P. Shetty sold 37,650 shares of the business’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $1.19, for a total transaction of $44,803.50. Following the sale, the insider now owns 13,616,994 shares of the company’s stock, valued at $16,204,222.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Barry Canton sold 75,300 shares of the business’s stock in a transaction on Tuesday, March 14th. The stock was sold at an average price of $1.33, for a total transaction of $100,149.00. Following the sale, the insider now directly owns 13,918,194 shares in the company, valued at approximately $18,511,198.02. The disclosure for this sale can be found here. Insiders have sold 512,604 shares of company stock valued at $666,890 in the last three months. 17.47% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

DNA has been the topic of several research reports. Raymond James cut their price objective on Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Friday, March 3rd. William Blair lowered Ginkgo Bioworks from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 11th. Finally, BTIG Research reduced their target price on Ginkgo Bioworks from $4.00 to $3.00 in a report on Sunday, March 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Ginkgo Bioworks currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Ginkgo Bioworks Trading Down 3.0 %

Shares of Ginkgo Bioworks stock opened at $1.28 on Friday. The firm has a fifty day moving average of $1.27 and a two-hundred day moving average of $1.65. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $1.12 and a 52 week high of $4.91.

Ginkgo Bioworks (NYSE:DNA – Get Rating) last announced its quarterly earnings results on Wednesday, March 1st. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.26. Ginkgo Bioworks had a negative net margin of 440.87% and a negative return on equity of 97.13%. The company had revenue of $98.29 million during the quarter, compared to analyst estimates of $84.41 million. Sell-side analysts predict that Ginkgo Bioworks Holdings, Inc. will post -0.29 earnings per share for the current year.

Ginkgo Bioworks Company Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.